David Kabakoff, PhD

David Kabakoff is an experienced biotechnology executive, with over 30 years of experience in leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields and 15 years of investing experience in therapeutics and molecular diagnostics. He is currently the Chairman of NextCure (NXTC), and Director of Antiva, Neurana and Rarecyte.. Previously he served as the Chairman of Trius and Amplimmune, and as a Director of InterMune and Principia. Prior to joining Sofinnova in 2007, David co-founded Salmedix, a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer until its acquisition by Cephalon. David also held the positions of Executive Vice President of Dura, a specialty pharmaceutical and pulmonary drug delivery company, and President and Chief Executive Officer of Spiros Development. Earlier, David was Chief Executive Officer of Corvas International and held senior executive positions with Hybritech. David received his PhD from Yale University and his BA from Case Western Reserve University. Prior to joining Sofinnova in 2007, David co-founded Salmedix, a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer until its acquisition of Salmedix by Cephalon. David also held the positions of Executive Vice President of Dura, a specialty pharmaceutical and pulmonary drug delivery company, and President and Chief Executive Officer of Spiros Development. Earlier, David was Chief Executive Officer of Corvas International and held senior executive positions with Hybritech.
David received his PhD from Yale University and his BA from Case Western Reserve University. He also serves as Director of Castle Biosciences (CSTL) and Rarecyte.